Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Revelation Biosciences (NASDAQ: REVB) has announced a special meeting of stockholders scheduled for January 17, 2025. The key focus is on Proposal 2, which involves redomiciling the company from Delaware to Nevada, potentially saving the company over $200,000 annually in franchise tax fees.
The Board of Directors recommends shareholders vote in favor of all proposals. The meeting will be held virtually via Zoom videoconference, with telephone participation options available. Shareholders can vote by contacting Advantage Proxy at the provided toll-free numbers.
Revelation Biosciences (NASDAQ: REVB) ha annunciato una riunione speciale degli azionisti prevista per il 17 gennaio 2025. L'argomento principale è Proposta 2, che prevede il trasferimento della sede legale della società dal Delaware al Nevada, con un potenziale risparmio per l'azienda di oltre $200,000 all'anno in tasse sulle licenze.
Il Consiglio di Amministrazione raccomanda agli azionisti di votare a favore di tutte le proposte. La riunione si svolgerà virtualmente tramite videoconferenza Zoom, con opzioni di partecipazione telefonica disponibili. Gli azionisti possono votare contattando Advantage Proxy ai numeri verdi forniti.
Revelation Biosciences (NASDAQ: REVB) ha anunciado una reunión especial de accionistas programada para el 17 de enero de 2025. El enfoque principal es la Propuesta 2, que implica trasladar la sede de la empresa de Delaware a Nevada, lo que potencialmente podría ahorrar a la empresa más de $200,000 anuales en tarifas de impuestos sobre franquicias.
La Junta Directiva recomienda a los accionistas votar a favor de todas las propuestas. La reunión se llevará a cabo virtualmente a través de videoconferencia por Zoom, con opciones de participación telefónica disponibles. Los accionistas pueden votar contactando a Advantage Proxy a los números gratuitos proporcionados.
Revelation Biosciences (NASDAQ: REVB)는 2025년 1월 17일로 예정된 주주 특별 회의를 발표했습니다. 주요 초점은 제안 2로, 회사 본사를 델라웨어에서 네바다로 이전하여 매년 $200,000 이상의 프랜차이즈 세금 비용을 절감할 가능성이 있습니다.
이사회는 주주들이 모든 제안에 찬성 투표할 것을 권장합니다. 회의는 Zoom 화상 회의를 통해 가상으로 진행되며, 전화 참여 옵션도 제공됩니다. 주주들은 제공된 무료 전화번호로 Advantage Proxy에 연락하여 투표할 수 있습니다.
Revelation Biosciences (NASDAQ: REVB) a annoncé une assemblée générale spéciale des actionnaires prévue pour le 17 janvier 2025. L'objectif principal est la Proposition 2, qui concerne le changement de domiciliation de la société du Delaware au Nevada, permettant ainsi à l'entreprise d'économiser potentiellement plus de $200,000 par an en frais d'impôt sur les franchises.
Le conseil d'administration recommande aux actionnaires de voter en faveur de toutes les propositions. La réunion se tiendra virtuellement via vidéoconférence Zoom, avec des options de participation téléphonique disponibles. Les actionnaires peuvent voter en contactant Advantage Proxy aux numéros verts fournis.
Revelation Biosciences (NASDAQ: REVB) hat eine spezielle Hauptversammlung der Aktionäre für den 17. Januar 2025 angekündigt. Der Schwerpunkt liegt auf Vorschlag 2, der einen Umzug des Unternehmens von Delaware nach Nevada umfasst, was dem Unternehmen potenziell über $200,000 jährlich an Franchise-Steuern sparen könnte.
Der Vorstand empfiehlt den Aktionären, für alle Vorschläge zu stimmen. Die Sitzung wird virtuell über eine Zoom-Videokonferenz abgehalten, mit verfügbaren Telefonteilnahmemöglichkeiten. Aktionäre können ihre Stimmen abgeben, indem sie Advantage Proxy unter den angegebenen gebührenfreien Nummern kontaktieren.
- Potential annual savings of $200,000 through redomiciling from Delaware to Nevada
- None.
Insights
The proposed redomiciliation from Delaware to Nevada represents a meaningful cost optimization initiative for a micro-cap company like Revelation Biosciences. The projected annual savings of
Nevada offers several advantages over Delaware for smaller public companies, including lower franchise taxes, reduced filing fees and stronger protection for corporate officers. This move aligns with prudent financial management practices, especially important for clinical-stage biotech companies that typically have high cash burn rates and revenue streams. The cost savings could extend the company's operational runway, though investors should note that this alone doesn't address the fundamental business challenges or development pipeline progress.
– A vote for Proposal 2 saves the Company over
Please vote by calling Advantage Proxy toll free at 877-870-8565 or 206-870-8565.
The Special Meeting of Stockholders will take place virtually via a Zoom videoconference. You can access the virtual meeting by using the following link: https://revbproxy.com/special-meeting
For more information on Revelation, please visit www.RevBiosciences.com.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Important Information
Revelation has filed a proxy statement with the Securities and Exchange Commission (SEC) in connection with the solicitation of proxies for the Special Meeting of Stockholders. Before making any voting decision, stockholders are urged to read the proxy statement in its entirety, which contains important information. Stockholders may obtain free copies of the proxy statement and other relevant documents at the SEC’s website (www.sec.gov) at https://www.sec.gov/Archives/edgar/data/1810560/000095017024136402/revb-20241213.htm. For additional information, please contact Advantage Proxy at 877-870-8565 or 206-870-8565.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113001825/en/
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
Source: Revelation Biosciences, Inc.
FAQ
When is Revelation Biosciences (REVB) special stockholder meeting in 2025?
How much will REVB save annually by moving from Delaware to Nevada?
How can shareholders vote for REVB's special meeting proposals?
How can shareholders attend REVB's virtual special meeting?
